SCHEMBL643135

SCHEMBL643135

O=C(CC1CCCCN1S(=O)(=O)c1ccc(Cl)c(Cl)c1)NCC1CCC(C(CCc2ccccc2)N2CCCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 4/20 0.39
TSHR P16473 1/20 0.39
FKBP1A P62942 5/20 0.39
MMP9 P14780 1/20 0.38
HTR7 P34969 2/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
HTR1E P28566 1/20 0.38
ADRA1B P35368 1/20 0.38
DRD3 P35462 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL642819 0.98 TSHR (0.41) BDKRB1TSHRFKBP1AMMP9HTR7
SCHEMBL644965 0.95 KMT2A (0.42) BDKRB1TSHRFKBP1A
SCHEMBL644254 0.93 KMT2A (0.44) BDKRB1TSHRMMP9HTR7HTR1A
SCHEMBL643142 0.89 BDKRB1 (0.43) BDKRB1TSHRFKBP1AMMP9HTR7
SCHEMBL644112 0.87 TSHR (0.43) BDKRB1TSHRMMP9HTR7HTR1A
SCHEMBL645044 0.86 TSHR (0.41) BDKRB1TSHRHTR7HTR1ADRD2
SCHEMBL643935 0.85 KMT2A (0.43) BDKRB1TSHR
SCHEMBL643083 0.85 TSHR (0.43) BDKRB1TSHRHTR7HTR1ADRD2
SCHEMBL644632 0.83 BDKRB1 (0.57) BDKRB1
SCHEMBL645050 0.82 KMT2A (0.46) BDKRB1TSHRHTR7HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP claimed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A BDKRB1 1566/4885TSHR 3623/4885FKBP1A 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.